On January 6, 2020 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, reported that data from studies utilizing Cchek, the company’s artificial intelligence (AI) driven cancer detection technology, will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Advances in Liquid Biopsies (Press release, Anixa Biosciences, JAN 6, 2020, View Source [SID1234552708]). The presentation will review data related to Anixa’s recently launched Cchek Prostate Cancer Confirmation test.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) conference takes place January 13 – January 16, 2020 at the Hilton Miami Downtown in Miami, Florida and is designed to showcase the latest advances in liquid biopsies and how they may be translated into the clinic. The meeting will be attended by U.S. and international basic scientists, translational researchers, and clinicians.
Details of the poster presentation are as follows:
Abstract title: Using pattern recognition neural networks to detect prostate cancer: a new method to analyze flow cytometry-based immunophenotyping using machine learning
Author: George Dominguez
Session: Poster Session B
Session Date and Start Time: Wednesday, January 15, 2020 at 12:30 p.m. ET
About Cchek
Cchek is an early cancer detection technology, that measures a patient’s immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient’s cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa’s orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek makes it a platform from which multiple cancer diagnostic tests may be developed. On December 16, 2019, Anixa announced the commercial launch of the Cchek Prostate Cancer Confirmation test (Cchek PCC), the first test developed with the Cchek liquid biopsy technology.